EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

2023.10.24
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.
APASL President Doctor Shuichiro Shiina Invites You to Attend the 2024 the Asian Pacific Association for the Study of the Liver Conference in Kyoto, Japan

APASL President Doctor Shuichiro Shiina Invites You to Attend the 2024 the Asian Pacific Association for the Study of the Liver Conference in Kyoto, Japan

2023.10.24
At the 58th European Association for the Study of the Liver (EASL) Annual Meeting, also known as EASL 2023 Congress, Professor Shuichiro Shiina, the President of the Asian Pacific Association for the Study of the Liver (APASL)  and a professor of gastroenterology at Juntendo University in Japan, was invited to attend the conference. He engaged in a stimulating roundtable discussion with hepatologists from various countries on the topic of "Hepatology and Hepatologists of the Future: Opportunities and Challenges." Hepatology Digest had the privilege of inviting Doctor Shuichiro Shiina to share his insights and experiences from his visit to EASL, as well as his expectations for the 2024 APASL Annual Meeting.
New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults

New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults

2023.10.23
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease globally and is independently associated with an increased risk of Type 2 Diabetes (T2DM) and cardiovascular diseases. Approximately one-third of the global population is currently facing the health threat posed by NAFLD, yet it appears that healthcare systems are not giving it enough attention. On the first day of the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Elisabetta Bugianesi from the Department of Digestive Internal Medicine at the University of Turin, Italy, urged the public to take NAFLD seriously. She provided a detailed overview of lifestyle interventions as a key means of preventing and treating NAFLD, sharing the latest research evidence, guideline recommendations, and future strategies. Hepatology Digest has compiled this report for the benefit of its readers.